VolitionRx unveils three colorectal cancer detection studies in Asia

Life sciences company VolitionRx Ltd (NYSEAMERICAN:VNRX) is broadening the reach of its clinical trial program with the announcement of new agreements to conduct three large-scale colorectal cancer research studies across Asia.
The Asian studies will add to the momentum behind VolitionRx's Nu.QTM colorectal cancer blood test, which is also being analyzed as part of big trials involving 45,000 Europeans and as many as 13,500 subjects in the US.
Volition today said it has signed agreements with National Taiwan University to conduct two large-scale studies, under the supervision of Professor Han-Mo Chiu, clinical professor with NTU's department of Internal Medicine, and Professor Takahisa Matsuda, director of the cancer screening center with the National Cancer Screening Hospital in Tokyo.
In addition to the research with National Taiwan University, VolitionRx has also signed an agreement for a 719-subject study to be run in collaboration with Professor Khay Guan Yeoh of the National University of Singapore.
All three studies are being conducted to test Volition's proprietary Nu.Q platform for the detection and diagnosis of colorectal cancer.
The first trial will include 5,000 subjects with no symptoms of colorectal cancer and the second will evaluate up to 2,000 patients with colorectal cancer.


Related news
- Yellow Diamonds - A Gap in the Diamond market
- Coffee with Samso: Episode 1, Australian Tungsten Projects and How the Chinese Market View The Tungsten sector
- Chasing for Kryptonite, the unknown other Lithium source
- What is In-Situ Recovery? Mining in a National Park with no environmental footprint
- Buds & Duds: Cannabis stocks drop but Weekend Unlimited shares jump on CBD hemp seed news
- Hemispherx treats first patient with cancer drug Ampligen in Phase 2 clinical trials
- THC Global granted cannabis Manufacture Licence, shares surge 20%